LIC reduces stake in Sun Pharma, sells shares worth Rs 3,882 crore in a little over one year
PTI, Jul 26, 2022, 9:54 AM IST
Credit: Reuters photo
Life Insurance Corporation on Monday said it has reduced shareholding in Sun Pharmaceuticals by selling 2 per cent stake in the company for about Rs 3,882 crore.
The shares were sold through open market transactions during the period from May 17, 2021 to July 22, 2022, according to a regulatory filing.
“This is to inform that corporation’s shareholding in Sun Pharamceuticals has diluted from 16,85,66,486 to 12,05,24,944 equity shares, decreasing its shareholding from 7.026 per cent of the paid-up capital of the said company,” it said.
Under Sebi norms, listed companies are required to intimate the stock exchanges when their shareholding in an entity falls by 2 per cent or more.
The shares were sold at an average price of Rs 808.02 apiece, valuing the transactions at a total of Rs 3,881.85 crore.
On the BSE, shares of LIC (Life Insurance Corporation) declined 0.70 per cent to close at Rs 684.15 apiece while that of Sun Pharmaceuticals fell 0.75 per cent to Rs 868.05 apiece.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Baku climate talks: The ‘X’ factor that could determine future of Global South
Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial
Gautam Adani charged in US with USD 250 mn bribery, fraud
India’s GDP growth likely to slip at 6.5 pc, maintains 7 pc estimate for FY25: Icra
RBI cautions public about ‘deepfake’ video of governor being circulated on social media
MUST WATCH
Latest Additions
Teen stabs man to death at railway station in Mumbai after quarrel over local train seat
War has endangered future of 2.5 billion children of world: UP CM Adityanath
UP man gets 10-yr jail term for murder attempt on father
Cement mixer truck overturns near Ambagilu
SC notice to Gujarat govt on Asaram’s plea seeking suspension of sentence in 2013 rape case
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.